Plasma Exosome RNA to Diagnose Prostate Cancer

Enrolling by invitation · Not applicable

Conditions studied: Prostate Cancer

In brief

The aim of the present study is to investigate a RNA combination to diagnose prostate cancer.

Key facts

Study ID

NCT06604130

Run by

Xijing Hospital

People needed

1600

Starts

2021-03-12

Expected to finish

2026-12-31

Last updated by the study team

2026-07-30

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: accepted.

You may qualify if…

• Blood prostate-specific antigen PSA\>4ng/dl;
• Patients suspected of having prostate cancer through clinical symptoms, digital rectal examination, ultrasound examination, magnetic resonance imaging, and PSMA PET/CT examination.
• The patient is willing to undergo prostate biopsy.

You may not qualify if…

• Previous diagnosis of prostate cancer through prostate biopsy;
• History of other malignant tumors in the past two years;
• According to the research physician\'s judgment, serious complications may occur and affect the normal conduct of the experiment

Where it is running

• The First Hospital of Lanzhou University — Lanzhou, Gansu, China
• General Hospital of Ningxia Medical University — Yinchuan, Ningxia, China
• Qinghai University Affiliated Hospital — Xining, Qinghai, China
• Weinan Central Hospital — Weinan, Shaanxi, China
• Shaanxi Provincial People's Hospital — Xi'an, Shaanxi, China
• Xijing 986 Hospital — Xi'an, Shaanxi, China
• Xijing Hospital — Xi'an, Shaanxi, China
• The Second Affiliated Hospital of Shaanxi University of Chinese Medicine — Xianyang, Shaanxi, China
• Affiliated Hospital of Yan'an University, — Yan’an, Shaanxi, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.